Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
细胞生物学 肿瘤
/
细胞培养
MAPK/ERK Pathway 肿瘤生长增殖和凋亡 乳腺癌 前列腺癌 肝癌 胰腺癌 结直肠癌
/
类器官培养添加剂
MEK
/ Selumetinib/司美替尼

Selumetinib/司美替尼 {[allProObj[0].p_purity_real_show]}

货号：A351367 同义名： 司美替尼 (AZD6244) / AZD6244; ARRY-142886

Selumetinib(AZD6244) 是一种选择性、非ATP竞争性口服MEK1/2抑制剂，对MEK1的IC50为14 nM，并抑制ERK1/2的磷酸化。

Selumetinib/司美替尼 化学结构 CAS号：606143-52-6
Selumetinib/司美替尼 化学结构
CAS号：606143-52-6
Selumetinib/司美替尼 3D分子结构
CAS号：606143-52-6
Selumetinib/司美替尼 化学结构 CAS号：606143-52-6
Selumetinib/司美替尼 3D分子结构 CAS号：606143-52-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Selumetinib/司美替尼 纯度/质量文件 产品仅供科研

货号：A351367 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 MEK ↓ MEK1 ↓ MEK1/2 ↓ MEK2 ↓ MEK5 ↓ 其他靶点 纯度
Honokiol ✔ 98%
Mirdametinib ++++

MEK, IC50: 0.33 nM

 		99%+
Binimetinib +++

MEK, IC50: 12 nM

 		99%+
BI-847325 ++

MEK1, IC50: 25 nM

 		+++

MEK2, IC50: 4 nM

 		99%+
U0126-EtOH +

MEK1, IC50: 0.07 μM

 		++

MEK2, IC50: 0.06 μM

 		98%
GDC-0623 ++++

MEK1, IC50: 0.13 nM

 		99%+
TAK-733 ++++

MEK1, IC50: 3.2 nM

 		99%+
Trametinib ++++

MEK1, IC50: 0.92 nM

 		++++

MEK2, IC50: 1.8 nM

 		99%+
Selumetinib +++

MEK1, IC50: 14 nM

MEK1, Kd: 99 nM

 		+

MEK2, Kd: 530 nM

 		99%+
CI-1040 ++

MEK1, IC50: 17 nM

 		++

MEK2, IC50: 17 nM

 		99%+
Myricetin ✔ 98%
Refametinib ++

MEK1, IC50: 19 nM

 		++

MEK2, IC50: 47 nM

 		99%+
Cobimetinib +++

MEK1, IC50: 4.2 nM

 		99%+
PD98059 +

MEK1, IC50: 2 μM

 		99%+
SL327 +

MEK1, IC50: 0.18 μM

 		+

MEK2, IC50: 0.22 μM

 		AP-1 98+%
PD318088 ✔ 99%
AZD8330 +++

MEK1/2, IC50: 7 nM

 		99%+
Pimasertib 98%
(E/Z)-BIX02189 ++++

MEK5, IC50: 1.5 nM

 		99%+
(E/Z)-BIX02188 +++

MEK5, IC50: 4.3 nM

 		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Selumetinib/司美替尼 生物活性

靶点

  • MEK2

    MEK2, Kd:530 nM

  • MEK1

    MEK1, IC50:14 nM

    MEK1, Kd:99 nM
描述 The Ras-Raf-MEK pathway is overactive in many human cancers, such as melanoma and NSCLC. Selumetinib, also called as ARRY-142886 or AZD6244, is a potent and highly selective MEK1/2 inhibitor with IC50 of 14 nM (measured by the catalytic activation of purified His-MEK1 on ERK2). Selumetinib can inhibit the enzymatic activity of MEK1/2 but not the MEK1/2 phosphorylation by Raf. IC50 of Selumetinib to inhibit MEK1/2 phosphorylation on ERK1/2 in cell lines examed is less than 40 nM. In EGFR-overexpressed A431 cells, EGF-induced ERK1/2 phosphorylation can be inhibited by Selumetinib at the concentration < 10 μM in a dose-dependent manner, while no obvious inhibition can be observed in ERK5. In cell growth study, Selumetinib shows more potent in cell lines containing activating B-Raf and Ras mutations (HT-29, Malme-3M, MIA PaCa-2, SK-MEL-2, SK-MEL-28 cells, IC50 values ranging from 59 to 473 nM), while it had no effect on other cell lines examined, including BxPC3, BT474 and Malme-3 cells with no Raf/Ras-mutantion reported. 21-day administration of selumetinib orally, BID, can inhibit the tumour growth up to 70% at the concentration of 100 mg/kg in mice bearing HT-29 tumors and inhibition of phospho-ERK1/2 was seen[1]. Selumetinib is mainly used in the study of melanoma, NSCLC, Neurofibromatosis type 1 etc.[2].
作用机制 Molecular modeling data shows Selumetinib can bind to the allosteric inhibitor binding site in MEK1/2[1].

Selumetinib/司美替尼 细胞实验

Cell Line
Concentration Treated Time Description References
A549 cells 1 µM 24 hours To study the effect of MEK inhibitors on KRAS-mutant lung cancer cells, it was found that MEK inhibitors including GDC-0623 enhanced HGF- and EGF-induced AKT phosphorylation. Mol Cancer Res. 2016 Oct;14(10):1019-1029.
NF1-mutant NF95.11b neuro fibroma cells 1 μM 48 h To test if PRC2 inactivation is sufficient for selumetinib resistance, results showed that PRC2 inactivation inhibited Schwann cell differentiation marker expression and attenuated selumetinib responses. Nat Commun. 2024 Jan 12;15(1):477.
Human monocyte-derived dendritic cells (mDC) 1 μM 48 h Selumetinib increased the expression of activation markers CD80, CD83, CD86, and HLA-DR on mDCs. J Immunother Cancer. 2017 Aug 15;5(1):63.
CT26 murine colon adenocarcinoma cells 0.123 μM 48 h Selumetinib increased the expression of H2-Kd class-I MHC proteins and decreased PD-L1 expression in CT26 cells. J Immunother Cancer. 2017 Aug 15;5(1):63.
Human peripheral blood mononuclear cells (PBMC) 5.8 nM (IC50) 72 h Selumetinib inhibited T-cell activation and reduced IL-2 secretion. J Immunother Cancer. 2017 Aug 15;5(1):63.
A172 cells 10 nM 24 h To evaluate the inhibitory effect of Selumetinib on GBM cell proliferation. The results showed that Selumetinib significantly inhibited TRIM22 overexpression-induced GBM cell proliferation. Exp Mol Med. 2023 Jun;55(6):1203-1217.
U251MG cells 10 nM 24 h To evaluate the inhibitory effect of Selumetinib on GBM cell proliferation. The results showed that Selumetinib significantly inhibited TRIM22 overexpression-induced GBM cell proliferation. Exp Mol Med. 2023 Jun;55(6):1203-1217.
Primary astrocytes 1 μM 48 h To study the effect of Selumetinib on the activity of primary astrocytes, the results showed that Selumetinib did not affect cell activity. J Neuroinflammation. 2022 Mar 14;19(1):67.
SUM149 0.1 μM and 1 μM 48 h To evaluate the effect of Selumetinib on cell cycle distribution, results showed that Selumetinib induced G1 arrest. Mol Cancer Ther. 2015 Dec;14(12):2773-81.
MDA-MB-231 0.1 μM and 1 μM 48 h To evaluate the effect of Selumetinib on cell cycle distribution, results showed that Selumetinib induced G1 arrest. Mol Cancer Ther. 2015 Dec;14(12):2773-81.
SUM149 0.001, 0.01, 0.1, 1, or 10 μM 72 h To evaluate the effect of Selumetinib on cell proliferation, results showed that Selumetinib did not significantly inhibit cell proliferation in 2D culture. Mol Cancer Ther. 2015 Dec;14(12):2773-81.
MDA-MB-231 0.001, 0.01, 0.1, 1, or 10 μM 72 h To evaluate the effect of Selumetinib on cell proliferation, results showed that Selumetinib did not significantly inhibit cell proliferation in 2D culture. Mol Cancer Ther. 2015 Dec;14(12):2773-81.
NF1-deficient human Schwann cells 10-100 nM 48 h To evaluate the cytotoxic effect of CQ on NF1-deficient human Schwann cells, results showed that CQ significantly reduced the viability of NF1/C0//C0 cells. Mol Oncol. 2025 Mar;19(3):825-851.
NF1-deficient Drosophila cells 1-10 µM 48 h To evaluate the cytotoxic effect of CQ on NF1-deficient cells, results showed that CQ significantly reduced the viability of dNF1-KO cells. Mol Oncol. 2025 Mar;19(3):825-851.

Selumetinib/司美替尼 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice KRAS-driven lung cancer mouse models Oral gavage 25 mg/kg Once daily for 4 weeks To evaluate the antitumor effect of the combination therapy of PP2A activator DT-061 and MEK inhibitor AZD6244 Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
Mice JW23.3 MPNST allograft model Oral 25 mg/kg Twice daily for 21 days To test the in vivo efficacy of Selumetinib, results showed that Selumetinib significantly inhibited the growth of MPNST allografts. Nat Commun. 2024 Jan 12;15(1):477.
Mice CT26 murine colorectal cancer model Oral 25 mg/kg Twice daily for 8 days Selumetinib reduced CD11b+Ly6G+ granulocytic cells in the tumor microenvironment, increased the frequency of CD11b+Ly6C+MHCII+ intermediate differentiating monocytes, and decreased the expression of Cox-2 and Arg1. J Immunother Cancer. 2017 Aug 15;5(1):63.
NOD/SCID mice GBM xenograft model Intraperitoneal injection 50 mg/kg Daily until the end of the experiment To evaluate the inhibitory effect of Selumetinib on GBM tumor growth. The results showed that Selumetinib significantly inhibited TRIM22 overexpression-induced GBM tumor growth and prolonged the survival of mice. Exp Mol Med. 2023 Jun;55(6):1203-1217.
Mice Intracerebral hemorrhage model In situ injection 5 mg/kg Single injection, lasting 10 minutes To study the therapeutic effect of Selumetinib on mice with intracerebral hemorrhage model, the results showed that Selumetinib improved the pathological indices and prognosis after intracerebral hemorrhage. J Neuroinflammation. 2022 Mar 14;19(1):67.
Female athymic nude mice Triple-negative breast cancer xenograft model Oral 50 mg/kg Daily for 3 weeks To evaluate the inhibitory effect of Selumetinib on lung metastasis, results showed that Selumetinib significantly reduced the incidence of lung metastasis. Mol Cancer Ther. 2015 Dec;14(12):2773-81.
Mice NF1-deficient MPNST xenograft model Intraperitoneal injection 50 mg/kg Three times per week for 3 weeks To evaluate the inhibitory effect of CQ on NF1-deficient tumors, results showed that CQ significantly slowed tumor growth, and the effect was superior to Selumetinib. Mol Oncol. 2025 Mar;19(3):825-851.

Selumetinib/司美替尼 动物研究

Dose Mice[3] (i.p.): min = 25 mg/kg, max = 100 mg/kg
Administration i.p.
Pharmacokinetics
Animal Nude mice[4]
Dose 10 mg/kg
Administration p.o.
Cmax 2977 ng/ml
T1/2 2.29 h
Tmax 1.0 h
AUC 17525 ng/(ml·h)
Vz/F 1.9 L/kg
Cl/F 0.6 L/(h·kg)

Selumetinib/司美替尼 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00085787 Advanced Cancer Phase 1 Completed - United States, Colorado ... 展开 >> University of Colorado Cancer Center, Anschutz Cancer Center Aurora, Colorado, United States, 80010 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 收起 <<
NCT00780676 Breast Cancer Phase 2 Terminated(Closed early for fu... 展开 >>tility.) 收起 << - United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02546661 Muscle Invasive Bladder Cancer Phase 1 Recruiting March 27, 2020 -

Selumetinib/司美替尼 参考文献

[1]Yeh TC, Marsh V, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007 Mar 1;13(5):1576-83.

[2]Bernabé R, Patrao A, et al. Selumetinib in the treatment of non-small-cell lung cancer. Future Oncol. 2016 Nov;12(22):2545-2560.

[3]Bartholomeusz C, Oishi T, et al. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther. 2012 Feb;11(2):360-9.

[4]Denton CL, Gustafson DL, et al. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother Pharmacol. 2011 Feb;67(2):349-60.

Selumetinib/司美替尼 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.18mL

0.44mL

0.22mL

10.92mL

2.18mL

1.09mL

21.85mL

4.37mL

2.18mL

Selumetinib/司美替尼 技术信息

CAS号606143-52-6
分子式C17H15BrClFN4O3
分子量 457.68
SMILES Code O=C(C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C3N=CN(C)C3=C1)NOCCO
MDL No. MFCD11977472
别名 司美替尼 (AZD6244) ;AZD6244; ARRY-142886; ARRY886; NSC 741O78; CL 1,040
运输蓝冰
InChI Key CYOHGALHFOKKQC-UHFFFAOYSA-N
Pubchem ID 10127622
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C
溶解方案

DMSO: 20 mg/mL(43.7 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
方案 三
配制的工作液建议现用现配，短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案 一

Tags: Selumetinib | 606143-52-6 | AZD6244 | ARRY-142886 | AZD 6244 | AZD-6244 | ARRY142886 | ARRY 142886 | ARRY-142886 | MEK1/2 Inhibitor | MAPK/ERK Pathway | Apoptosis | MEK | Apoptosis | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Selumetinib/司美替尼 纯度/质量文件 | Selumetinib/司美替尼 亚型比较 | Selumetinib/司美替尼 生物活性 | Selumetinib/司美替尼 动物研究 | Selumetinib/司美替尼 临床数据 | Selumetinib/司美替尼 参考文献 | Selumetinib/司美替尼 实验方案 | Selumetinib/司美替尼 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z